Tye MA, Payne C, Johansson C, et al. Elucidating the path to Plasmodium prolyl-tRNA synthetase inhibitors that overcome halofuginone resistance. Nat Commun. 2022;13(1):4976. doi:10.1038/s41467-022-32630-4.

Chen R, Zhang J, Wu Y, et al. Monoacylglycerol lipase is a therapeutic target for Alzheimer’s disease. Cell Rep. 2012;2(5):1329-39. doi:10.1016/j.celrep.2012.09.030.

Wan Y, Feng G, Calakos N. Sapap3 deletion causes mGluR5-dependent silencing of AMPAR synapses. J Neurosci. 2011;31(46):16685-91. doi:10.1523/JNEUROSCI.2533-11.2011.

Wong GS, Zhou J, Bin Liu J, et al. Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med. 2018;24(7):968-977. doi:10.1038/s41591-018-0022-x.

Golfmann K, Meder L, Koker M, et al. Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer. Oncogene. 2018;37(42):5682-5693. doi:10.1038/s41388-018-0380-3.

Tarumoto Y, Lin S, Wang J, et al. Salt-inducible kinase inhibition suppresses acute myeloid leukemia progression in vivo. Blood. 2020;135(1):56-70. doi:10.1182/blood.2019001576.

Gräff J, Kahn M, Samiei A, et al. A dietary regimen of caloric restriction or pharmacological activation of SIRT1 to delay the onset of neurodegeneration. J Neurosci. 2013;33(21):8951-60. doi:10.1523/JNEUROSCI.5657-12.2013.

Herman JD, Rice DP, Ribacke U, et al. A genomic and evolutionary approach reveals non-genetic drug resistance in malaria. Genome Biol. 2014;15(11):511. doi:10.1186/PREACCEPT-1067113631444973.

Herman JD, Pepper LR, Cortese JF, et al. The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs. Sci Transl Med. 2015;7(288):288ra77. doi:10.1126/scitranslmed.aaa3575.

Kim YK, Lee J-S, Bi X, et al. The binding of fluorophores to proteins depends on the cellular environment. Angew Chem Int Ed Engl. 2011;50(12):2761-3. doi:10.1002/anie.201007626.